BRD4

Overview

BRD4 (bromodomain-containing protein 4) is a member of the BET (bromodomain and extra-terminal domain) family of epigenetic reader proteins. It recognizes acetylated lysine residues on histones through its bromodomains and helps regulate chromatin-associated transcription, including RNA polymerase II–mediated gene expression. Because of this role, BRD4 is widely studied as a regulator of cell growth, survival, and oncogenic transcriptional programs.

In biomedical research, BRD4 is an important therapeutic target in cancer and other disease contexts where transcriptional control is dysregulated. Inhibition or degradation of BRD4 can suppress expression of tumor-driving genes, alter signaling pathways such as NF-κB signaling and Wnt/β-catenin pathway-related programs, and affect processes including proliferation, ferroptosis sensitivity, and viral latency-associated protein expression.

Recent Publications Focus

Below is a summary of the newest research publications targeting BRD4 (sorted by publication date).

BRD4 remains an attractive therapeutic target across multiple disease contexts, with recent research expanding the arsenal of targeting strategies. Beyond conventional inhibitors, proteolysis-targeting chimeras (PROTACs) have emerged as particularly promising agents for inducing potent, selective BRD4 degradation. A novel RIMTAC platform recruits VHL for BRD4 degradation through indirect RIPK1 hijacking, demonstrating concentration- and time-dependent degradation that is UPS-dependent [42417401]. Complementary PROTAC designs using diyne-based linkers achieve low nanomolar BRD4 degradation while enabling label-free intracellular visualization via stimulated Raman scattering microscopy [42094781].

Innovative delivery systems have expanded the therapeutic reach of BRD4-targeting agents to tissue compartments previously difficult to access. An inhalable polymeric PROTAC nanococktail was engineered to deliver BRD4-degrading molecules to fibrotic lung lesions in idiopathic pulmonary fibrosis, where dual targeting of STING and BRD4 achieved superior efficacy compared to single PROTAC therapy [42341263]. In castration-resistant prostate cancer, a nanozyme-mediated PROTAC platform combines MIL-101 nanoparticles with hyaluronic acid modification to achieve CD44-targeted delivery and GSH-triggered BRD4-PROTAC release, while simultaneously inducing ferroptosis [41870961].

BRD4-targeting approaches have demonstrated efficacy across diverse malignancies through both direct inhibition and degradation strategies. In metastatic castration-resistant prostate cancer, a dual BRD4/AKT inhibitor was designed to overcome c-MYC-driven resistance, achieving 62.0% tumor growth inhibition in vivo [41966583]. BRD4 PROTAC degraders have proven effective against KSHV-infected endothelial cells through suppression of LANA translation [42224297]. In pancreatic ductal adenocarcinoma, HDAC inhibition redistributes histone acetylation away from chromatin regions containing BRD4 and RNA polymerase II at DNA damage response gene promoters, sensitizing tumors to genotoxic and DDR-targeting agents [42348617]. An 8-sulfonamidoquinoline derivative has demonstrated potent anti-proliferative activity in colorectal cancer through inhibition of nuclear factor kappa B and Wnt/β-catenin signaling pathways [41763019], while BRD4 has been identified as a critical regulator of super-enhancer-driven oncogenic programs in acute megakaryoblastic leukemia [42310709].

Single-molecule analytical techniques have advanced understanding of BRD4-drug interactions at unprecedented resolution. Nanopore sensing with YaxAB nanopores enables discrimination of BRD4-small-molecule drug complexes at near-atomic resolution, detecting mass differences as small as 2.5 Da [42046448], offering new capabilities for drug discovery and diagnostics.